Understand the source comparison
Benefits of Pancragen Versus Evidence Strength
The benefits of Pancragen are not equally supported across outcomes. Glucose and insulin-resistance claims have limited human evidence, pancreatic differentiation claims are cell-culture evidence, and anti-aging or broad metabolic claims remain insufficiently
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- The benefits of Pancragen are not equally supported across outcomes. Glucose and insulin-resistance claims have limited human evidence, pancreatic differentiation claims are cell-culture evidence, and anti-aging or broad metabolic claims remain insufficiently established for clinical conclusions.
- Older adults with type 2 diabetes
- Fasting glucose, glucose tolerance, insulin, and insulin resistance index in 33 older patients with type 2 diabetes [1]
- Early human evidence
- Suggests possible metabolic effects in a small study; cannot establish broad diabetes treatment efficacy
- Old rhesus monkeys
- Glucose, insulin, C-peptide, and glucose tolerance after Pancragen exposure [5], [15]
- Preclinical primate evidence
- Helps explore endocrine-function hypotheses; cannot replace human clinical trials
- Streptozotocin diabetic rats
- Blood glucose, capillary permeability, and endothelial adhesion in Wistar rats [3]
- Preclinical animal evidence
- Shows diabetes-model effects in rats; translation to humans is uncertain
- Pancreatic cell cultures
- Differentiation markers including Pdx1, Pax6, Pax4, Foxa2, and NKx2.2 [2]
- In vitro evidence
- Supports mechanism hypotheses; cannot prove symptom or disease outcomes
- Regulatory status
- FDA approval requires product-specific review of safety, effectiveness, and labeling [7], [12]
- Regulatory context
- Clarifies that research discussion is not the same as approval